Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12227440 | 0.89 | MCHR1 (0.38) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL12227441 | 0.89 | MCHR1 (0.38) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL12227442 | 0.89 | MCHR1 (0.38) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL23502255 | 0.80 | NPY5R (0.41) | EPHX2L3MBTL3NPY5RSMN1; SMN2ALDH1A1 | |
| SCHEMBL4550247 | 0.79 | L3MBTL3 (0.58) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL17062871 | 0.79 | EPHX2 (0.41) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL12227445 | 0.79 | ALDH1A1 (0.35) | EPHX2KDM4EEPHX1ALDH1A1 | |
| SCHEMBL23328554 | 0.79 | TEAD1 (0.41) | L3MBTL3 | |
| SCHEMBL19710577 | 0.78 | KDM4E (0.45) | EPHX2KDM4EEPHX1L3MBTL3NPY5R | |
| SCHEMBL14997483 | 0.78 | EPHX2 (0.43) | EPHX2KDM4EEPHX1L3MBTL3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | EPHX2 4379/4885KDM4E 2703/4885EPHX1 3844/4885 |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | EPHX2 3595/4885KDM4E 938/4885EPHX1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.